Opendata, web and dolomites

HOXA9 degradome SIGNED

Deciphering the machinery involved in stability of the transcription factor HOXA9.

Total Cost €


EC-Contrib. €






 HOXA9 degradome project word cloud

Explore the words cloud of the HOXA9 degradome project. It provides you a very rough idea of what is the project "HOXA9 degradome" about.

crispr    elucidate    global    combat    hoxa9    malignancy    degradation    carcinogenesis    assessing    regulators    clinical    interference    mutated    candidate    skills    screen    machinery    outcome    perturbation    integrating    suitable    dkfz    genes    career    platform    strategies    nodes    drive    amenable    strategy    inhibition    positive    hematopoiesis    50    stability    direct    hits    flexible    limitation    undoubtedly    aml    cas9    molecular    dissection    critical    proteins    aggressive    leukemia    attractive    medical    followed    school    initiation    acquire    druggable    heidelberg    degradome    aberrantly    shows    summary    usa    acute    employing    master    harvard    pharmacologic    facs    elevated    abundance    network    tool    specificity    proteomics    library    regulatory    expressed    scientific    plan    therapeutic    screening    data    overcome    progression    regulates    patients    alternative    controls    cancer    validate    protein    transcription    milestone    performing    poor    intensify    myeloid    expression    levels    pharmaceutical   

Project "HOXA9 degradome" data sheet

The following table provides information about the project.


Organization address
postcode: 69120

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 239˙860 €
 EC max contribution 239˙860 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2016
 Duration (year-month-day) from 2016-11-07   to  2019-11-06


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor that controls a network of genes critical for hematopoiesis. It shows increased expression levels in more than 50% of patients with acute myeloid leukemia (AML), and is strongly associated with poor clinical outcome. Since the initiation and progression of AML depend on elevated HOXA9 levels, it represents an attractive therapeutic target to combat this aggressive malignancy. However, transcription factors are often not amenable to direct pharmacologic inhibition. To overcome this limitation, an alternative strategy aiming at interference with the transcription factor-specific 'degradome' - the degradation machinery regulates HOXA9 stability. To this end, we aim to elucidate the HOXA9 degradome with the goal of identifying its druggable nodes. Specifically, we plan to (1) identify regulatory proteins involved in the degradation of HOXA9 by performing a FACS-based positive selection screen with a focused CRISPR/Cas9 library as perturbation tool, (2) validate candidate proteins involved in the control of HOXA9 stability, and (3) characterize hits suitable for pharmacologic targeting. For the most promising HOXA9 regulators, we will determine their specificity by assessing global changes of protein abundance by proteomics. The potential of employing hits for pharmaceutical targeting will be evaluated by integrating molecular information with clinical data. In summary, this project aims to establish novel strategies for the dissection of the transcription factor HOXA9 degradome by developing a flexible screening platform. Through this project, I will not only acquire new skills but also establish a scientific network, which is expected to intensify the collaboration between DKFZ and Harvard Medical School. Two years’ experience in USA followed by one year in Heidelberg will be undoubtedly a milestone in my career development.


year authors and title journal last update
List of publications.
2018 Quinlan L. Sievers, Georg Petzold, Richard D. Bunker, Aline Renneville, Mikołaj Słabicki, Brian J. Liddicoat, Wassim Abdulrahman, Tarjei Mikkelsen, Benjamin L. Ebert, Nicolas H. Thomä
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
published pages: eaat0572, ISSN: 0036-8075, DOI: 10.1126/science.aat0572
Science 362/6414 2019-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOXA9 DEGRADOME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOXA9 DEGRADOME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Biochip-images (2019)

A Breast Cancer Biomarker Point of CarePOCDiagnostic Platform Integrating Dual-Functionalized Nanoparticle for Magnetic Gradient Ranking and Electrochemical Sensing

Read More  

ROAR (2019)

Investigating the Role of Attention in Reading

Read More  

MAREITA (2018)

Mapping Remediation in Italian Literature Beyond the Digital Revolution

Read More